5.00
0.24 (5.04%)
| Penutupan Terdahulu | 4.76 |
| Buka | 4.82 |
| Jumlah Dagangan | 3,963,901 |
| Purata Dagangan (3B) | 4,123,241 |
| Modal Pasaran | 1,331,830,528 |
| Harga / Buku (P/B) | 6.25 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.880 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 43.67% |
| Nisbah Semasa (MRQ) | 3.40 |
| Aliran Tunai Operasi (OCF TTM) | -206.18 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -118.45 M |
| Pulangan Atas Aset (ROA TTM) | -23.84% |
| Pulangan Atas Ekuiti (ROE TTM) | -71.44% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Sana Biotechnology, Inc. | Menurun | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.38 |
|
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 8.46% |
| % Dimiliki oleh Institusi | 89.37% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Flagship Pioneering, Llc | 30 Sep 2025 | 25,001,856 |
| Crestline Management, Lp | 30 Sep 2025 | 1,820,937 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 9.00 (HC Wainwright & Co., 80.00%) | Beli |
| Median | 7.50 (50.00%) | |
| Rendah | 6.00 (Wedbush, 20.00%) | Beli |
| Purata | 7.50 (50.00%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 4.36 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| B of A Securities | 06 Jan 2026 | 7.00 (40.00%) | Beli | 4.36 |
| HC Wainwright & Co. | 07 Nov 2025 | 9.00 (80.00%) | Beli | 4.09 |
| Wedbush | 07 Nov 2025 | 6.00 (20.00%) | Beli | 4.09 |
| Citizens | 30 Oct 2025 | 8.00 (60.00%) | Beli | 4.90 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 07 Jan 2026 | Pengumuman | Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 08 Dec 2025 | Pengumuman | Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform |
| 24 Nov 2025 | Pengumuman | Sana Biotechnology to Present at December 2025 Investor Conferences |
| 06 Nov 2025 | Pengumuman | Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates |
| 04 Nov 2025 | Pengumuman | Sana Biotechnology to Present at the TD Cowen Immunology & Inflammation Summit |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |